A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors by Becher, Oren J. et al.
  
This is the author manuscript accepted for publication and has undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/pbc.26409. 
 
This article is protected by copyright. All rights reserved. 
Title: A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors  
 
Authors: Oren J. Becher, MD, Stephen W. Gilheeney, MD, Yasmin Khakoo, MD, David C. Lyden, 
MD, PhD, Sofia Haque, MD, Kevin C. De Braganca, MD, Jill M. Kolesar, Pharm D, Jason T. Huse, 
MD, PhD, Shakeel Modak, MD, Leonard H. Wexler, MD, Kim Kramer, MD, Ivan Spasojevic, PhD, 
and Ira J. Dunkel, MD
 
 
Affiliations: Departments of Pediatrics
 
(OJB, SWG, YK, DCL, KCD, SM, LHW, KK, IJD), 
Radiology (SH), and Pathology (JTH), Memorial Sloan Kettering Cancer Center, New York, NY 
10065, Departments of Pediatrics (OJB) and Medicine (IS), Duke University Medical Center, 
Durham, NC 27710, Department of Pediatrics (YK, DCL, LHW, IJD) and Radiology (SH), Weill 
Cornell Medical College, New York, NY 10065, and the School of Pharmacy (JMK), University of 
Wisconsin, Madison, WI 53703 
 
Correspondence should be directed to: Dr. Ira Dunkel, Memorial Sloan Kettering Cancer Center, 
Box 185, 1275 York Avenue, New York, NY 10065. Telephone: 212-639-2153, Fax: 212-717-3239, 
e-mail: dunkeli@mskcc.org 
 
  
This article is protected by copyright. All rights reserved. 
2 
 
Word counts: Abstract 250, Main text (excluding title page, abstract, reference, tables, figures & 
legends) 3425 
Number of figures: 2 
Number of tables: 4 
 
Running title: Phase I pediatric perifosine and temsirolimus 
Key Words: Perifosine, Temsirolimus, AKT, mTOR, Phase I clinical trials 
 
Abbreviation Key table:  
AKT protein kinase B 
AST aspartate transaminase 
AUC area under the curve 
CL clearance 
Cmax maximum concentration 
DIPG diffuse intrinsic pontine glioma 
DLT dose-limiting toxicity 
FDA Food and Drug Administration 
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IRB Institutional Review Board 
MSKCC Memorial Sloan Kettering Cancer Center 
MTD maximum tolerated dose 
mTOR mammalian Target of rapamycin 
mTORC mammalian target of rapamycin complex 
PI3K phosphoinositide 3-kinase 
PK pharmacokinetic 
PTEN phosphatase and tensin homolog 
t1/2 half-life 
Vss volume of distribution at steady state 
 
Abstract 
Background: The PI3K/AKT/mTOR pathway is aberrantly activated in many pediatric solid tumors 
including gliomas and medulloblastomas. Preclinical data in a pediatric glioma model demonstrated 
that the combination of perifosine (AKT inhibitor) and temsirolimus (mTOR inhibitor) is more potent 
at inhibiting the axis than either agent alone. We conducted this study to assess pharmacokinetics and 
to identify the maximally tolerated dose for the combination. 
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Procedure: We performed a standard 3+3 phase I, open-label, dose escalation study in patients with 
recurrent/refractory pediatric solid tumors. Four dose levels of perifosine (25 to 75 mg/m2/day) and 
temsirolimus (25 to 75 mg/m2 IV weekly) were investigated.  
Results: 23 patients (median age 8.5 years) with brain tumors (diffuse intrinsic pontine glioma 
[DIPG] n=8, high-grade glioma n=6, medulloblastoma n=2, ependymoma n=1), neuroblastoma (n=4), 
or rhabdomyosarcoma (n=2) were treated. The combination was generally well tolerated and no dose 
limiting toxicity was encountered. The most common grade 3 or 4 toxicities (at least possibly related) 
were thrombocytopenia (38.1%), neutropenia (23.8%), lymphopenia (23.8%) and 
hypercholesterolemia (19.0%). Pharmacokinetic findings for temsirolimus were similar to those 
observed in the temsirolimus single agent phase II pediatric study and pharmacokinetic findings for 
perifosine were similar to those in adults. Stable disease was seen in 9 of 11 subjects with DIPG or 
high-grade glioma; no partial or complete responses were achieved. 
 
Conclusions: The combination of these AKT and mTOR inhibitors was safe and feasible in patients 
with recurrent/refractory pediatric solid tumors. 
 
Introduction 
New agents are desperately needed for relapsed pediatric solid tumors because of their very poor 
outcome and the lack of effective salvage strategies. The phosphoinositide 3-kinases (PI3Ks) are a 
family of lipid enzymes which phosphorylate the phosphatidylinositols on the plasma membrane. 
They transmit signals received from activated tyrosine kinase receptors, G protein-coupled receptors, 
and activated Ras to molecules such as protein kinase B (AKT) and mammalian Target of rapamycin 
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(mTOR) that control cell metabolism, proliferation, size, and survival.[1] Activated PI3K recruits 
AKT to the cell membrane and activates it, which can indirectly activate mammalian target of 
rapamycin complex (mTORC) 1 which consists of mTOR, the catalytic subunit of this complex, and 
several other proteins. Activation of mTORC1 results in increased protein synthesis, cell growth, 
survival and proliferation.[2] An important negative regulator of PI3K/AKT/mTOR signaling is 
phosphatase and tensin homolog (PTEN), which is a lipid phosphatase that antagonizes the kinase 
activity of PI3K. 
 
The PI3K/AKT/mTOR axis is aberrantly activated in a variety of cancers including pediatric solid 
tumors through gene amplification or mutation upstream at the level of the receptor (e.g., activating 
mutations in platelet-derived growth factor receptor-alpha, anaplastic lymphoma kinase, and 
fibroblast growth factor receptor 1, activating mutations in one of the subunits of PI3K, or inactivating 
mutations of the negative regulator PTEN.[3-8] AKT activation has been associated with a poorer 
outcome in neuroblastoma and with other markers of aggressive disease.[9] Similarly, PTEN loss has 
been noted to be a poor prognostic factor in pediatric high-grade gliomas and 
medulloblastomas.[10,11] In addition, there is evidence that the PI3K/AKT/mTOR pathway may also 
play an important role in resistance to radiation and/or chemotherapy.[12,13] 
 
Perifosine, a synthetic alkylphospholipid, represents a new class of antitumor agents that act on cell 
membranes rather than on DNA. Perifosine’s primary mechanism of action is thought to be through 
interference with the recruitment of AKT to the plasma membrane resulting in inhibition of AKT 
phosphorylation and activation.[14,15] Perifosine also has other mechanisms of action such as 
inhibition of de novo synthesis of cell membrane components.[15] 
  
This article is protected by copyright. All rights reserved. 
6 
 
 
Temsirolimus is an ester derivative of sirolimus or rapamycin, a naturally occurring drug produced by 
a soil bacterium.[16] Both rapamycin and temsirolimus are inhibitors of mTORC1. However, mTOR 
can also form a second complex called mTORC2, which is insensitive to temsirolimus and sirolimus 
and is known to activate AKT.[16] Temsirolimus is FDA approved for the treatment of renal cell 
carcinoma. Recently, temsirolimus has been evaluated in children with solid tumors as a single agent 
(high-grade glioma, neuroblastoma, and rhabdomyosarcomas) with prolonged stable disease in some 
patients.[17] This suggests that inhibiting the mTOR pathway is a promising approach but that 
targeting a single molecule may not be adequate to achieve significant anti-tumor activity. 
 
Research over the past decade has unraveled multiple feedback loops in this pathway and the 
scientific rationale for this study is the observation that mTOR inhibition alone with rapalogs like 
rapamycin or temsirolimus results in AKT activation through upregulation of receptor tyrosine kinase 
signaling.[18-20] In addition, AKT inhibition induces the expression and activation of multiple 
activated tyrosine kinase receptors.[1] Preclinical evaluation of perifosine and temsirolimus in a 
pediatric glioma model demonstrated that significant inhibition of both AKT and mTOR occurred 
only when both drugs were given together.[21] Therefore this phase I clinical study of perifosine in 
combination with temsirolimus (two targeted agents that inhibit different points of the same pathway) 
was developed to evaluate the preclinical findings of synergy in targeting the PI3K/AKT/mTOR 
pathway between the two drugs as observed in this preclinical model of glioma. 
 
Methods 
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The primary aim of the study was to determine the maximum tolerated dose (MTD) of the 
combination of perifosine and temsirolimus in patients with recurrent or refractory pediatric solid 
tumors. Secondary aims were to (1) determine whether pharmacokinetic (PK) serum levels of 
perifosine and temsirolimus correlate with toxicity, (2) assess preliminary data on the efficacy of the 
perifosine and temsirolimus combination, and (3) determine whether molecular features of the tumor 
were associated with likelihood of response. 
 
Patients 
Between February 10, 2010 and August 21, 2012, 23 patients with recurrent or refractory pediatric 
solid tumors were enrolled onto the study. One enrolled subject never received study prescribed 
therapy and is not included in this analysis (Figure 1). Twenty of the 22 treated subjects were less than 
18 years old. The other two were young adults (21 and 24 years old). 
 
Eligibility criteria included: (1) presence of any solid tumor that had failed standard therapy, (2) 
evidence of tumor by computed tomography, magnetic resonance imaging, or 
metaiodobenzylguanidine scan, serum markers, or tissue sampling, (3) age ≤ 21 years (age ≤ 35 years 
for biopsy proven medulloblastoma or neuroblastoma), (4) Karnofsky or Lansky performance status ≥ 
50%, (5) adequate organ function [absolute neutrophil count ≥ 1000 at least 24 hours off filgrastim, 
platelet count ≥ 100,000/mcL at least 1 week post-platelet transfusion, hemoglobin ≥ 8g/dL at least 1 
week post- packed red blood cell transfusion, aspartate transaminase (AST) and alanine transaminase 
≤ 2 x the upper limits of normal, total bilirubin ≤ 2 mg/dL, serum creatinine ≤ 1.5 x the upper limit of 
normal for age, or calculated creatinine clearance or nuclear glomerular filtration rate ≥ 70 
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ml/min/1.73 m2], (6) adequate lipid profile [cholesterol level < 350 mg/dL and triglycerides level < 
400 mg/dL], (7) mandated interval since prior therapy [≥ 3 weeks since last non-nitrosourea 
chemotherapy, ≥ 6 weeks since last nitrosoureas, ≥ 4 weeks since last radiation therapy], (8) ability to 
swallow tablets whole, and (9) agreement to practice adequate contraception and not breast feed. Prior 
exposure to single-agent perifosine and/or an mTOR inhibitor was permitted as long as the agent had 
not been associated with a dose-limiting toxicity (DLT). Exclusion criteria included (1) pregnancy, (2) 
uncontrolled active infection, (3) patients with human immunodeficiency virus receiving combination 
anti-retroviral therapy, (4) enzyme-inducing anti-convulsant usage, and (5) history of pulmonary 
hypertension or pneumonitis. The subjects (if adults or emancipated minors) or parents or legal 
guardians of all patients gave informed consent. The Memorial Sloan Kettering Cancer Center 
(MSKCC) Institutional Review Board (IRB) and the Food and Drug Administration (FDA) approved 
the protocol. 
 
Treatment protocol 
This was a standard 3+3 phase I dose escalation study in which doses of both drugs were escalated. 
Four dose levels were investigated (Table 1). Temsirolimus was administered weekly, intravenously 
over 30 minutes following antihistamine pre-medication, at either 25 or 75 mg/m2/dose. Perifosine 
was only available as 50 mg tablets. A loading dose was administered on day 1 and then the 
maintenance dose was administered every 1 to 4 days, depending on the dose level and body surface 
area of the subject. The complete dosing scheme is given in Table 1. Treatment was continued until 
disease progression, intolerable toxicity, DLT or death was encountered. Subjects experiencing DLT 
after 2 cycles of treatment, but with evidence of clinical benefit, were eligible to remain on study with 
a dose level reduction. Some treatable laboratory abnormalities that were not associated with any 
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signs or symptoms originally met the DLT definition, but the MSKCC IRB and the FDA approved an 
amendment to exclude them. 
 
Subjects were seen weekly for assessment and temsirolimus treatment. Laboratory assessments 
(complete blood count, coagulation studies, chemistries, lipid profiles) were performed weekly during 
cycle 1 and then every other week. Tumor assessments were performed about every 8 weeks. 
 
Toxicity was assessed according to the Common Toxicity Criteria (version 3.0) of the National 
Cancer Institute, National Institutes of Health. Dose-limiting toxicity was defined in the final version 
of the protocol as (1) any non-hematological toxicity grade ≥ 3 [except for grade 3 nausea, vomiting, 
and diarrhea that could be controlled within 24 hours with supportive care measures, grade 3 or 4 
electrolyte abnormalities that could be corrected by medical management or grade 3 or 4 cholesterol 
or triglyceride abnormality], (2) grade 4 neutropenia on 2 consecutive blood counts drawn at least 72 
hours apart, (3) grade 4 febrile neutropenia or grade 4 documented infection with absolute neutrophil 
count < 1,000/mcL, (4) grade 3 thrombocytopenia with bleeding or a platelet count < 25,000/mcL. 
 
Correlative studies 
Samples for PK analyses were obtained at baseline and during cycle 1. Serum for perifosine levels 
was obtained on days 1, 8, 15 and 22 of cycle 1. One blood sample for temsirolimus and sirolimus 
levels was obtained pre-infusion on days 1, 8 and 22; on day 15 samples were obtained pre-infusion 
and at hours 1, 6 and 24. 
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Perifosine: At each time point, heparinized blood (7 to 10 ml) was collected into a plastic vacutainer 
to minimize adhesion of perifosine. Plasma was separated by centrifugation and stored in 
polypropylene cryovials at -80°C until assayed. Perifosine in plasma was measured by a validated 
reversed phase liquid chromatography/electrospray mass spectrometry method as previously 
described.[22] 
 
Temsirolimus: At each time point, whole blood (2 ml) was collected into an 
ethylenediaminetetraacetic acid -treated tube and stored at -80°C until assayed. Concentrations of 
temsirolimus and sirolimus were measured by a validated liquid chromatography/tandem-mass 
spectrometry assay with internal standards at SFBC-Taylor (Princeton, NJ). Standard PK parameters 
such as maximum concentration (Cmax), area under the curve (AUC), half-life (t1/2), clearance (CL), 
and volume of distribution at steady state (Vss) were calculated using non-compartmental approach 
using WinNonlin 6.3 software (Pharsight Corp). 
 
Tumor tissue: Five micron formalin-fixed paraffin-embedded sections were used for all 
immunostaining procedures. Immunohistochemical staining was performed on a Discovery Ultra 
autostainer (Ventana Medical Systems, Tucson, AZ, USA) using the following antibodies and 
concentrations: PTEN (1:100) (cat# 9559, Cell Signaling Technology, Davers, MA, USA), p-AKT 
S473 (1:100) (cat#4060, Cell Signaling Technology), p-PRAS40 (1:40) (cat# 2997, Cell Signaling 
Technology). Stains were developed with standard DAB-based reagents with the exception of p-AKT, 
which employed multimeric chemistry (OmniMap anti-RB, Ventana Medical Systems). Following 
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staining, slides were dehydrated in graded alcohols and coverslipped manually with Permount 
mounting media (Sigma-Aldrich, St. Louis, MO, USA). 
 
Response criteria 
For subjects with tumors other than neuroblastoma, responses were assessed via RECIST.[23] For 
subjects with neuroblastoma, the International Neuroblastoma Response criteria were used.[24] 
 
Statistics 
The DLT assessment period was the first 28 day cycle. If therapy was discontinued during the 
first cycle for reasons other than toxicity, an additional subject could be enrolled at that dose 
level to ensure adequate evaluation of toxicity. No intra-patient dose escalation was 
permitted. 
 
Results 
Patient Characteristics  
The median age of the 22 subjects was 9 years (range 4 to 24 years). Eleven (50%) were male and 11 
female. Sixteen subjects had central nervous system tumors (DIPG n=8, high-grade astrocytoma n=5, 
medulloblastoma n=2, ependymoma n=1), 4 had neuroblastoma, and 2 had rhabdomyosarcoma. Table 
2 contains additional details regarding patient characteristics. 
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Number of Cycles 
The entire group of subjects initiated a total of 62 cycles of treatment. A median of 2 cycles was 
administered per patient, with a range from <1 to 6 cycles. Two subjects withdrew consent during the 
first cycle (not due to toxicity) and were replaced.  
 
Toxicity 
Table 3 contains a summary of toxicities considered at least possibly related to perifosine and/or 
temsirolimus including all hematologic toxicities and non-hematologic toxicities seen in > 10% of 
subjects or at least grade 3 (even if seen in < 10% of subjects). The perifosine and temsirolimus 
combination was generally well tolerated. The most common toxicities of any grade (at least possibly 
related) were hyperglycemia (95.2%), fatigue (90.5%), increased AST (81%), decreased hemoglobin 
(81%), and decreased platelets (81%), with the vast majority of these toxicities ≤ grade 2. The most 
common grade 3 or 4 toxicities (at least possibly related) were thrombocytopenia (38.1%), 
neutropenia (23.8%), lymphopenia (23.8%) and hypercholesterolemia (19.0%). 
 
No subject suffered a DLT based on the criteria described in the Methods section above. The original 
version of the study included more stringent DLT definitions and 3 subjects suffered DLT. On dose 
level 2 one subject had grade 3 hypokalemia that spontaneously resolved 1 day later and on dose level 
3 one subject each had grade 4 hypercholesterolemia and grade 3 hypophosphatemia.  
 
Responses 
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Nineteen subjects were evaluable for response and the results are detailed in Table 2. Three were 
considered inevaluable due to withdrawal of consent (n=2) and early removal from study (n=1) within 
the first month, prior to any response evaluation. 
 
Five subjects with recurrent high-grade glioma were treated on study. One went off study after only 9 
days due to electrolyte abnormalities (not considered to be DLT) and so was not evaluable for 
response. Four were evaluable for response and their best responses were stable disease (n=3) for 2, 2, 
and 4 months and progressive disease (n=1). None of them were treated on combined dose level 4, 
which is being proposed as the recommended phase 2 dose. 
 
Eight subjects with recurrent DIPG were treated on study. One went off study due to withdrawal of 
consent following an infusion reaction (hives, cough, and hypoxia that responded promptly to 
supportive care) associated with the first dose of temsirolimus (not considered to be DLT) and so was 
not evaluable for response. Seven were evaluable for response and their best responses were stable 
disease (n=6) for 1.5, 2, 2, 4, 4 and 4 months and progressive disease (n=1). The 5 DIPG patients 
treated at the proposed phase 2 dose all had stable disease at first evaluation. 
 
Four subjects with neuroblastoma were treated on study. All 4 had no response to treatment as 
evaluated after the first cycle of therapy. Three had progressive disease after 4 cycles and 1 received 
only 1 cycle of therapy before withdrawing consent. 
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Pharmacokinetics 
PK calculations for perifosine were possible from 18 patients. Perifosine plasma 
concentration was measured weekly (steady state levels) and presented in Figure 2. Average 
steady state levels of perifosine were calculated for each dose level. Linear dose response was 
found (Figure 2; average steady-state level vs. average actual daily dose given), albeit rather 
large inter-patient (especially in dose group 3) and in some cases intra-patient variability as 
illustrated in Figure 1. The average perifosine steady-state values were correlated with PK 
parameters obtained for temsirolimus and sirolimus; correlation coefficients are given in 
Supplemental Table S1. Despite some strong correlations found in case of dose group 1, the 
overall trend observed across dose groups and statistical power available is not enough to 
suggest that perifosine interferes with temsirolimus metabolism. The steady-state perifosine 
levels are similar to steady-state levels reported in clinical trials with perifosine for adults 
with cancer.[25] 
 
PK calculations for temsirolimus and sirolimus were possible from 18 and 17 patients, 
respectively. PK parameters for temsirolimus and its major active metabolite, sirolimus, are 
listed in Supplemental Table S1. Large inter-patient variability in temsirolimus Cmax 
measurements was observed, which was less pronounced with sirolimus and is in line with 
other studies.[17] There was no clear correlation pattern observed between perifosine steady-
state levels and temsirolimus/sirolimus PK parameters.  
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Tumor tissue biological assays 
Eight subjects had DIPG tumors that had never been biopsied and tumor tissue was 
unavailable from 7 other subjects. The results of the biological assays performed on 7 
subjects’ tumor tissue are presented in Table 2. 
 
Discussion 
To the best of our knowledge, this is the first published experience regarding a clinical trial employing 
both AKT and mTOR inhibition. The most notable finding is that this is tolerable and joint 
AKT/mTOR inhibition potentially could be developed further with the addition of other agents. 
 
There are few prior publications regarding the use of temsirolimus in pediatric oncology patients. 
Spunt et al treated 18 subjects at 10 to 150 mg/m2/dose weekly. One of 18 had DLT (grade 3 
anorexia) at the 150 mg/m2/weekly dose level, but no MTD was identified. One subject with 
neuroblastoma achieved complete response; 5 other subjects achieved stable disease, 3 for more than 
4 months (ependymoma, germ cell tumor, adrenocortical carcinoma).[26] The same group 
subsequently performed a phase II trial of temsirolimus in 52 children with high-grade glioma, 
neuroblastoma or rhabdomyosarcoma. They used a dose of 75 mg/m2/dose weekly and only 1 partial 
response (in a patient with neuroblastoma) was achieved. Stable disease at week 12 was seen in 7 of 
17 patients with high-grade glioma, 6 of 19 with neuroblastoma, and 1 of 16 with 
rhabdomyosarcoma.[17] 
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Our team hypothesized that the failure of mTOR inhibition monotherapy might be due to 
compensatory AKT activation and that simultaneous inhibition of mTOR and AKT might be more 
effective. Prior to the initiation of this study a pediatric phase I study of single-agent perifosine 
opened at MSKCC and the preliminary safety data supported the development of this combination 
trial. The single-agent perifosine data will be published separately. The only other pediatric clinical 
experience with an AKT inhibitor that we are aware of was a phase I trial of MK-2206 conducted by 
the Children’s Oncology Group.[27] Fifty children received MK-2206 orally on 2 schedules: every 
other day (n=23 evaluable) or weekly (n=17 evaluable). The recommended phase II dose was 
determined to be 45 mg/m2/dose every other day or 120 mg/m2/dose weekly. No objective response 
was observed; 7 subjects had stable disease for at least 3 courses (n=2 with ependymoma; n=1 each 
with malignant paraganglioma, gliomatosis, juvenile pilocytic astrocytoma, malignant peripheral 
nerve sheath tumor, and clear cell sarcoma). 
 
The perifosine and temsirolimus combination has also been investigated in 34 adults with recurrent or 
refractory malignant gliomas, but thus far only reported in abstract form.[28] The MTD of perifosine 
was determined to be a 600 mg load, then 100 mg daily with temsirolimus 115 mg weekly. Two 
partial responses were achieved, but at a dose level that used a higher temsirolimus dose (170 mg) 
than the MTD. 
 
The PK analysis of both perifosine and temsirolimus demonstrated large interpatient variability with 
perifosine steady state plasma levels in this pediatric cohort that are similar to those observed in adult 
studies and temsirolimus blood levels that are similar to those observed in the temsirolimus single 
agent phase II pediatric trial in a similar patient population suggesting that perifosine does not 
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interfere with the metabolism of temsirolimus. While the correlation between the perifosine dose 
administered and steady state plasma levels observed in this study suggest a linear dose response for 
perifosine at the dose range tested, this relationship should be interpreted with caution due to the large 
interpatient variability. By contrast, some perifosine studies in the adult population have observed an 
absence of a dose response at similar doses.[25, 29] In support of these latter observations are 
unpublished results from our phase I study of perifosine alone in children with recurrent solid tumors 
in which 25, 50, 75, 100, and 125 mg/m
2
/day dose levels were investigated, and no dose response was 
observed beyond 50 mg/m
2
/day (personal communication, Becher & Dunkel). 
 
In conclusion, the combination of perifosine and temsirolimus is well tolerated in children with 
recurrent solid tumors. Although this was a phase I study, the lack of objective responses suggest that 
this combination may need to be combined with additional agent(s) in the future. We did not assess 
target inhibition in tumor tissue in response to the therapy so it is not clear whether we were 
successful in inhibiting the PI3K/AKT/mTOR pathway in our subjects’ tumors. As most of the 
patients on the study had brain tumors, it is pertinent to know whether adequate levels of these drugs 
got to these tumors. Recently, the cerebrospinal fluid penetration of perifosine as a surrogate for 
blood-brain-barrier penetration was assessed in normal rhesus monkeys and was noted to be poor.[30] 
By contrast, another recent study identified the receptor for docosahexaenoic acid in endothelium of 
the blood-brain-barrier of mice and also noted that alkylphospholipids such as miltefosine may enter 
through this receptor.[31] Therefore, future studies with this combination particularly in brain tumor 
patients should investigate whether adequate concentrations of these drugs reach their targets. 
 
Supplemental Table S1. Detailed pharmacokinetic results. 
  
This article is protected by copyright. All rights reserved. 
18 
 
 
Acknowledgments 
Preliminary results of this study were presented at the Society for Neuro-oncology’s 2011 Pediatric 
Neuro-Oncology Basic and Translational Research Conference in New Orleans, LA. Funding was 
provided by the National Institutes of Health/National Cancer Institute Cancer Center Support Grant 
P30 CA008748; the National Comprehensive Cancer Network Oncology Research Program; Pfizer, 
Inc; Aeterna Zentaris. 
 
Conflict of Interest Statement 
Dr. Ira Dunkel would like to disclose that after the completion of this clinical trial he began serving as 
a consultant for Pfizer, but not regarding temsirolimus, the Pfizer agent that is the subject of this 
investigation. 
 
References 
1. Chandarlapaty S, Sawai A, Scaltriti M, et al. AKT inhibition relieves feedback suppression of 
receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19:58-71. 
2. Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and 
cancer: an updated review. Ann Med. 2014;46:372-383. 
  
This article is protected by copyright. All rights reserved. 
19 
 
3. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine 
gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as 
potential therapeutic targets. J Clin Oncol. 2010;28:1337-1344. 
4. Shukla N, Ameur N, Yilmaz I, et al. Oncogene mutation profiling of pediatric solid tumors reveals 
significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in 
growth signaling pathways. Clin Cancer Res. 2012;18:748-757. 
5. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer 
medulloblastoma. Science. 2011;331:435-439. 
6. Paugh BS, Zhu X, Qu C, et al. Novel oncogenic PDGFRA mutations in pediatric high-grade 
gliomas. Cancer Res. 2013;73:6219-6229. 
7. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial 
neuroblastoma predisposition gene. Nature. 2008;455:930-935. 
8. Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in 
pilocytic astrocytoma. Nat Genet. 2013;45:927-932. 
9. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of AKT predicts poor outcome in 
neuroblastoma. Cancer Res. 2007;67:735-745. 
10. Thorarinsdottir HK, Santi M, McCarter R, et al. Protein expression of platelet-derived growth 
factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. 
Clin Cancer Res. 2008;14:3386-3394. 
11. Castellino RC, Barwick BG, Schniederjan M, et al. Heterozygosity for Pten promotes 
tumorigenesis in a mouse model of medulloblastoma. PloS One. 2010;5:e10849. 
  
This article is protected by copyright. All rights reserved. 
20 
 
12. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. 
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following 
radiation in medulloblastoma in vivo. Genes Dev. 2008;22:436-448. 
13. Li Z, Oh DY, Nakamura K, Thiele CJ. Perifosine-induced inhibition of AKT attenuates brain-
derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer. 
2011;117:5412-5422. 
14. van Blitterswijk WJ, Verheij M. Anticancer mechanisms and clinical application of 
alkylphospholipids. Biochim Biophys Acta. 2013;1831:663-674. 
15. Fensterle J, Aicher B, Seipelt I, Teifel M, Engel J. Current view on the mechanism of action of 
perifosine in cancer. Anticancer Agents Med Chem. 2014;14:629-635. 
16. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and 
ageing. Nat Rev Mol Cell Biol. 2011;12:21-35. 
17. Geoerger B, Kieran MW, Grupp S, et al. Phase II trial of temsirolimus in children with high-grade 
glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer. 2012;48:253-262. 
18. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase 
signaling and activates AKT. Cancer Res. 2006;66:1500-1508. 
19. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of 
AKT signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932-1940. 
20. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway 
activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118:3065-
3074. 
  
This article is protected by copyright. All rights reserved. 
21 
 
21. Pitter KL, Galban CJ, Galban S, et al. Perifosine and CCI 779 co-operate to induce cell death and 
decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PloS 
One. 2011;6:e14545. 
22. Woo EW, Messmann R, Sausville EA, Figg WD. Quantitative determination of perifosine, a novel 
alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-
electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl. 2001;759:247-257. 
23. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in 
solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute 
of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216. 
24. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for 
neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477. 
25. Figg WD, Monga M, Headlee D, et al. A phase I and pharmacokinetic study of oral perifosine 
with different loading schedules in patients with refractory neoplasms. Cancer Chemother Pharmacol. 
2014;74:955-967. 
26. Spunt SL, Grupp SA, Vik TA, et al. Phase I study of temsirolimus in pediatric patients with 
recurrent/refractory solid tumors. J Clin Oncol. 2011;29:2933-2940. 
27. Fouladi M, Perentesis JP, Phillips CL, et al. A phase I trial of MK-2206 in children with refractory 
malignancies: a Children’s Oncology Group study. Pediatr Blood Cancer. 2014;61:1246-1251. 
28. Kaley TJ, Pentsova E, Omuro AMP, et al. Phase I trial of temsirolimus and perifosine for 
recurrent or progressive malignant glioma [abstract]. J Clin Oncol. 2013;31:2095. 
  
This article is protected by copyright. All rights reserved. 
22 
 
29. Van Ummersen L, Binger K, Volkman J, et al. A phase I trial of perifosine (NSC 639966) on a 
loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res. 
2004;10:7450-7456. 
30. Cole DE, Lester-McCully CM, Widemann BC, Warren KE. Plasma and cerebrospinal fluid 
pharmacokinetics of the AKT inhibitor, perifosine, in a non-human primate model. Cancer 
Chemother Pharmacol. 2015;75:923-928. 
31. Nguyen LN, Ma D, Shui G, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid 
docosahexaenoic acid. Nature. 2014;509:503-506. 
  
This article is protected by copyright. All rights reserved. 
23 
 
Figure legends 
Figure 1. Flow diagram regarding the enrolled subjects. 
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Figure 2. (A) Steady state plasma concentration of perifosine at weeks 2, 3, and 4 plotted for each 
study subject (1-24) across perifosine/combination dose groups; enumerated individual subject trace; 
grey semi-transparent thick line represents the average trace for the given dose group. Large inter-
patient and occasionally intra-patient variability observed. (B) Correlation plot of perifosine steady 
state plasma concentration versus daily dose (actually administered); error bars represent single 
standard deviation; enumerated combination dose groups. The excellent correlation observed supports 
linear dose response (i.e. linear PK) in the dose range utilized but should be interpreted with caution 
due to the large inter-patient variability. 
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TABLE 1. Dose Escalation Scheme 
Combination 
dose level 
Perifosine 
dose level 
Temsirolimus 
dose 
BSA Loading dose 
day 1 
Maintenance 
dose 
1 1 25 mg/m2 0.4 to 0.59 50 mg 50mg every 4 
days 
   0.6 to 0.79 50 mg 50mg every 3 
days 
   0.8 to 1.2 100 mg 50mg every 2 
days 
   1.21 to 1.6 150 mg 50mg 5 days 
per week 
   > 1.6 150 mg 50mg daily 
2 1 75 mg/m2 0.4 to 0.59 50 mg 50mg every 4 
days 
   0.6 to 0.79 50 mg 50mg every 3 
days 
   0.8 to 1.2 100 mg 50mg every 2 
days 
   1.21 to 1.6 150 mg 50mg 5 days 
per week 
   > 1.6 150 mg 50mg daily 
3 2 75 mg/m2 0.4 to 0.59 100 mg 50mg every 2 
days 
   0.6 to 0.79 100 mg 50 mg daily 5 
days per week 
   0.8 to 1.2 100 mg BID 50mg daily 
   1.21 to 1.6 150 mg BID 100mg daily 5 
days per week 
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   > 1.6 150 mg BID 100mg daily 
4 3 75 mg/m2 0.4 to 0.59 100 mg 50 mg daily 5 
days per week 
   0.6 to 0.79 100 mg 50mg daily 
   0.8 to 1.2 100 mg BID 50mg 
alternating 
with 100mg 
daily 
   1.21 to 1.6 150 mg BID 100mg daily 
   > 1.6 150 mg BID 100mg 
alternating 
with 150mg 
daily 
Perifosine dose level 1 aim 25 mg/m2, mean dose (SD) achieved: 25.92 (3.61). Perifosine dose level 2 
aim 50 mg/m2, mean dose (SD) achieved: 51.73 (8.36). Perifosine dose level 3 aim 75 mg/m2, mean 
dose (SD) achieved: 74.60 (11.59). 
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TABLE 2. Patient Characteristics and Responses 
Patient Dose 
level 
Age Sex Dx Prior 
RT  
# prior 
Cx 
regimens 
Best 
response 
(duration) 
pAKT PTEN pPRAS40 
1 1 7 F HGG Yes 3 PD Negative Negative Positive 
2 1 4 M MB Yes 4 PD    
3 1 11 M NB Yes 9 NR (1 mo) Negative Positive Negative 
4 2 24 M NB Yes 3 NR (4 mo) Negative Negative Negative 
5 2 9 F NB Yes 2 NR (4 mo) Negative Negative Negative 
6 2 4 F DIPG Yes 2 SD (4 mo)    
7 2 9 F HGG Yes 1 SD (4 mo) AF AF AF 
8 2 4 M DIPG Yes 3 PD    
9 3 10 M RMS Yes 2 PD Positive Negative Positive 
10 3 9 F HGG Yes 2 SD (2 mo)    
11 3 9 F MB Yes 5 PD    
12 3 17 M HGG Yes 2 SD (2 mo) Positive Positive Positive 
13 3 21 M HGG Yes 6 IE    
14 3 6 F NB Yes 3 NR (4 mo)    
15 4 8 M DIPG Yes 0 SD (4 mo)    
16 4 5 M DIPG Yes 1 PD    
17 4 5 F DIPG Yes 0 SD (1.5 
mo) 
   
18 4 5 F RMS Yes 5 IE    
19 4 5 F DIPG Yes 0 IE    
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20 4 15 M DIPG Yes 0 SD (4 mo)    
21 4 10 M DIPG Yes 0 SD (2 mo)    
22 4 9 F Ep Yes 2 PD    
Legend: AF=assay failure, Cx=chemotherapy, DIPG=diffuse intrinsic pontine glioma, Dx=diagnosis, 
Ep=ependymoma, F=female, HGG=high-grade glioma, IE=inevaluable for response, M=male, 
MB=medulloblastoma, mo=months, NB=neuroblastoma, NR=no response per INRC, PD=progressive 
disease, RMS=rhabdomyosarcoma, RT=radiation therapy, Rx=treatment, SD=stable disease 
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TABLE 3. Toxicity Summary 
  Any Grade Grade 3 or 4 
Hematologic Adverse 
Events 
No. % No. % 
Decreased 
hemoglobin 
17 80.95% 1 4.76% 
Decreased platelets 17 80.95% 8 38.09% 
Decreased leukocytes 13 61.90% 2 9.52% 
Increased PTT 11 52.38% 1 4.76% 
Decreased 
neutrophils 
9 42.85% 5 23.80% 
Increased INR 9 42.85% 0 0 
Lymphopenia 5 23.80% 5 23.80% 
Nonhematologic 
Adverse Events 
    
Hyperglycemia 20 95.23% 2 9.52% 
Fatigue (asthenia, 
lethargy, malaise) 
19 90.47% 0 0 
Increased AST 17 80.95% 2 9.52% 
Increased ALT 15 71.42% 3 14.28% 
Anorexia 13 61.90% 0 0 
Hypercholesterolemia 13 61.90% 4 19.04% 
Vomiting 13 61.90% 0 0 
Hypertriglyceridemia 13 61.90% 1 4.76% 
Hypokalemia 11 52.38% 2 9.52% 
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Constipation 10 47.61% 0 0 
Nausea 9 42.85% 0 0 
Hypernatremia 9 42.85% 1 4.76% 
Pain - Head/headache 8 38.09% 0 0 
Hypophosphatemia 8 38.09% 1 4.76% 
Urinary 
frequency/urgency 
7 33.33% 0 0 
Hyponatremia 6 28.57% 3 14.28% 
Fever (in the absence 
of neutropenia) 
6 28.57% 0 0 
Diarrhea 6 28.57% 0 0 
Mood alteration - 
Agitation 
6 28.57% 0 0 
Muscle weakness - 
Whole body/general 
6 28.57% 0 0 
Hypoalbuminemia 6 28.57% 0 0 
Pain - Joint 5 23.80% 0 0 
Pain - Stomach 5 23.80% 0 0 
Urinary retention 4 19.04% 0 0 
Pain - Extremity-limb 4 19.04% 0 0 
Hemorrhage, Nose 3 14.28% 0 0 
Mood alteration - 
Anxiety 
3 14.28% 0 0 
Ocular/Visual - Other 
(eye discharge) 
3 14.28% 0 0 
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Allergic rhinitis 3 14.28% 0 0 
Hypoglycemia 3 14.28% 0 0 
Infection w/ ≥ grade 3 
neutropenia, Urinary 
tract NOS 
1 4.76% 1 4.76% 
Notes: Toxicities considered to be at least possibly related. Non-hematological toxicities seen in > 10 
% of subjects 
 
 
